Treatment of EGFR-driven cancer with fewer side effects
The present invention provides methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI to delay or reverse acquired resistance to previously administered EGFR-TKIs. In addition, methods for treating a EGFR-mutant cancer in a patient by administering a selective CDK4/6 inhibitor described herein in combination or alternation with an EGFR-TKI are provided wherein an intrinsically EGFR-TKI resistant EGFR-mutant cancer is sensitized to the effects of the EGFR-TKI.
1. A method of treating a human with non-small cell lung cancer (NSCLC) having an epidermal growth factor receptor (EGFR) mutation, wherein the mutation is i) a substitution of threonine with methionine at amino acid 790 (T790M) and ii) a deletion in exon 19 (ex19del), comprising:
administering an effective amount of a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor of the structure:
or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI), wherein the EGFR-TKI is osimertinib.
2. The method of claim 1 , wherein the CDK4/6 inhibitor and osimertinib are both administered orally at least once daily.
3. The method of claim 1 , wherein the NSCLC, prior to administration of the CDK4/6 inhibitor and osimertinib, has developed acquired resistance to a previously administered EGFR-TKI treatment, wherein the acquired resistance developed by the NSCLC is to an EGFR-TKI selected from the group consisting of afatinib, erlotinib, gefitinib, and dacomitinib.
4. A method of treating a human with non-small cell lung cancer harboring an EGFR-activating mutation, wherein the EGFR activating mutation is an exon 19 deletion (ex19del), comprising administering an effective amount of a cyclin dependent kinase 4/6 (CDK 4/6) inhibitor of the structure:
or a pharmaceutically acceptable salt thereof, in combination with an effective amount of an EGFR-TKI, wherein the EGFR-TKI is osimertinib.
5. The method of claim 4 , wherein at the time of administration of the CDK4/6 inhibitor and osimertinib, the human has not previously been administered an EGFR-TKI.
6. The method of claim 4 , wherein the CDK4/6 inhibitor and osimertinib are both administered orally at least once daily.
7. The method of claim 4 , wherein the exon 19 deletion comprises a deletion of amino acids leucine, arginine, glutamic acid, and alanine (LREA).